Revenues

12 Months Ended

Dec. 31, 2021

Revenues

Revenues

Note 2. Revenues

As discussed in Note 1, revenues are recognized under guidance within ASC 606. The following table presents our disaggregated revenue for the periods presented (in thousands):

	For the Years Ended,
	December 31,
	2021		2020		2019
JAKAFI revenues, net	$	2,134,508	$	1,937,850	$	1,684,968
ICLUSIG revenues, net		109,395		105,002		89,954
PEMAZYRE revenues, net		68,531		25,884		—
MINJUVI revenues, net		4,910		—		—
OPZELURA revenues, net		4,668		—		—
Total product revenues, net		2,322,012		2,068,736		1,774,922
JAKAVI product royalty revenues		337,991		277,902		225,913
OLUMIANT product royalty revenues		220,875		110,920		80,424
TABRECTA product royalty revenues		10,389		4,144		—
Total product royalty revenues		569,255		392,966		306,337
Milestone and contract revenues		95,000		205,000		77,500
Total revenues	$	2,986,267	$	2,666,702	$	2,158,759

For further information on our revenue-generating contracts, refer to Note 6.